Gilead Sciences (GILD) Quarterly Report Leads to Morgan Stanley Reassessment

AI Summary

Morgan Stanley has reassessed its outlook for Gilead Sciences (GILD) following the company's recent quarterly report. GILD reported revenue of $6.36 billion for the last quarter, reflecting a year-over-year decrease of 4%. The company's earnings per share (EPS) were reported at $1.58, slightly below analysts' expectations of $1.60. This reassessment by Morgan Stanley could influence investor sentiment and GILD's stock performance in the near term.